A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418
Recruiting now · Phase 1 · Has a placebo group
Conditions studied: Parkinson Disease Psychosis, Amyotrophic Lateral Sclerosis (ALS)
In brief
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics and pharmacodynamics of oral doses of FB418 in healthy adult subjects and healthy elderly subjects.
Key facts
- Study ID
- NCT05995782
- Run by
- 1ST Biotherapeutics, Inc.
- People needed
- 64
- Starts
- 2023-12-20
- Expected to finish
- 2024-12-01
- Last updated by the study team
- 2024-12-02
Who can join
Age: 19 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- Seoul National University — Seoul, South Korea (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.